Long-term survival with glioblastoma multiforme.
By D. Krex, B. Klink, C. Hartmann, A. von Deimling, T. Pietsch, M. Simon, M. Sabel, J. Steinbach, O. Heese, Guido Reifenberger and 2 more. Brain : a journal of neurology, 2007
907 citations recorded by the source corpus.
Subfields: Cancer Research, Genetics
View Paper: https://www.semanticscholar.org/paper/735decf3292ee2687d7a5ae859c2ba324109eb2c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Genetics
Citations in the corpus
- Survival in glioblastoma: a review on the impact of treatment modalities (2016, background): “[9, 55], primary GBM were followed for a median of 7 years.”
- Matrix metalloproteinases in the brain and blood–brain barrier: Versatile breakers and makers (2016, background): “Levels of MMPs-1, -2, -3, -7, -8, -9, -13, MT1-, 2-, 3-, 5-, and MT6-MMP were also increased in brain tumors compared to non-cancerous brain tissue.(253,274,279,280) The same MT-MMPs activate proMMP-2 and proMMP-13, and activity and protein expression levels of those MT-MMPs correlate with proMMP-2 ”
- Glioblastoma: pathology, molecular mechanisms and markers (2015, background): “1 3 clinical progression in patients with WHO grade II tumors, to very short median survival times of 12–18 months in patients with WHO grade IV tumors (GBM); however, long-term survival extending the span of three years has been described in a fraction of GBM patients [88].”
- MGMT promoter methylation in malignant gliomas: ready for personalized medicine? (2010, background): “14 Nevertheless, long-term survival can be observed even in the absence of MGMT promoter methylation, indicating that MGMT promoter methylation is only one aspect of a very complex biological system.(44,45) A study published this year proposed that the extent of MGMT methylation, as”